Macular Telangiectasia Type 2 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Macular telangiectasia (MacTel) type 2 is a bilateral retinal disorder of unknown etiology, characterized by distinct alterations in the macular capillary network and neurosensory atrophy. Initially, the disease manifests temporally to the foveal center and may expand to encompass an oval region with approximate dimensions of 6° horizontally and 5° vertically centered on the foveola. The onset of symptoms typically occurs during the fifth or sixth decade of life, and a subset of patients reports a positive family history. Due to limited awareness among both clinicians and patients, MacTel type 2 is often diagnosed belatedly and may be misidentified as age-related macular degeneration in cases involving neovascularization. The prevalence of MacTel type 2 is rare, estimated at approximately 0.10%, with no significant gender or racial predilections. The mean age of onset is approximately 55 years. Notably, up to 45% of individuals with MacTel type 2 also present with comorbid conditions such as diabetes mellitus, obesity, hypertension, or cardiovascular diseases, which, along with smoking, may elevate the risk of clinical manifestation. Clinically, patients often present with unilateral or bilateral progressive blurred vision. Additional symptoms include metamorphopsia and paracentral scotomas, which can be effectively monitored using Amsler grid testing. Currently, there is no well-established treatment for MacTel type 2, though several interventions aim to prevent further vision loss or slow disease progression:
1. Anti-vascular endothelial growth factor (anti-VEGF) injections: These injections inhibit a chemical in the eye that promotes the growth of abnormal blood vessels, thereby reducing swelling, slowing leakage, and potentially improving vision. Anti-VEGF therapy is the standard care for the proliferative phase of MacTel.
2. Revakinagene taroretcel (NT-501): This encapsulated cell therapy has shown potential in slowing the progression of MacTel.
3. Ciliary neurotrophic factor (CNTF): Preliminary results are promising, but further research is needed to establish its efficacy.
Other treatment modalities for MacTel include focal and grid laser photocoagulation, photodynamic therapy (PDT), intravitreal triamcinolone acetonide (IVTA), and subretinal surgery.

Thelansis’s “Macular Telangiectasia Type 2 Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Macular Telangiectasia Type 2 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Macular Telangiectasia Type 2 across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Macular Telangiectasia Type 2 Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Macular Telangiectasia Type 2 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033